A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma

Launched by SICHUAN BAILI PHARMACEUTICAL CO., LTD. · Feb 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called BL-B01D1 for patients with recurrent or metastatic urothelial carcinoma, a type of bladder cancer that has not responded to previous treatments, including chemotherapy and certain immunotherapies. The goal of this phase III trial is to see how well BL-B01D1 works compared to standard chemotherapy chosen by the doctor. The trial is currently recruiting participants who are at least 18 years old and have a life expectancy of at least 3 months. Eligible patients should have advanced bladder cancer that cannot be surgically removed and have already tried specific treatments without success.

Participants in the trial can expect to receive either BL-B01D1 or the chosen chemotherapy. Throughout the study, their health will be closely monitored to assess the treatment's effectiveness and any side effects. It's important for potential participants to know that they will need to provide tumor tissue samples and meet certain health criteria, such as having manageable heart health and no active infections. This trial offers a chance to access a new therapy that may help those with limited treatment options for their cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Sign the informed consent form voluntarily and follow the protocol requirements;
• • 2. Age: ≥18 years old;
• • 3. Expected survival time ≥3 months;
• • 4. Patients with unresectable locally advanced or metastatic urothelial carcinoma who had failed platinum-based chemotherapy and PD-1/PD-L1 inhibitors;
• • 5. Patients with locally advanced or metastatic urothelial carcinoma who are eligible for treatment with the control chemotherapy agents specified in this protocol;
• • 6. Consent to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;
• • 7. At least one measurable lesion meeting the RECIST v1.1 definition was required;
• • 8. ECOG 0 or 1;
• • 9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
• • 10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
• • 11. If blood transfusion and colony-stimulating factor were not allowed within 14 days before randomization, the organ function level had to meet the requirements;
• • 12. A serum pregnancy test must be performed within 7 days before the start of treatment for premenopausal women of childbearing potential, and the result must be negative and must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.
• Exclusion Criteria:
• • 1. Chemotherapy, targeted therapy, biological therapy, etc. were used within 4 weeks or 5 half-lives before randomization;
• • 2. Patients with locally advanced or metastatic urothelial carcinoma who were suitable for radical local therapy were excluded;
• • 3. Frontline received ADCs targeting topoisomerase I inhibitors or EGFR and/or HER3; The front line had received both paclitaxel and docetaxel;
• • 4. History of severe heart disease and cerebrovascular disease;
• • 5. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;
• • 6. Prolonged QT interval, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
• • 7. Diagnosed with active malignancy within 3 years before randomization;
• • 8. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 100 mmHg);
• • 9. Patients with poor glycemic control;
• • 10. Patients with grade ≥1 radiation pneumonitis according to the RTOG/EORTC definition; Previous history of ILD, or suspicion of such disease during screening;
• • 11. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;
• • 12. Patients with active central nervous system metastases;
• • 13. Severe infection occurred within 4 weeks before randomization; Evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;
• • 14. Patients with massive or symptomatic effusions or poorly controlled effusions;
• • 15. Imaging examination indicated that the tumor had invaded or wrapped around the large blood vessels of the abdomen, chest, neck, and pharynx, except for those that the investigator thought would not affect the patient's enrollment in the drug;
• • 16. Serious unhealed wound, ulcer or fracture within 4 weeks before signing the informed consent;
• • 17. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
• • 18. Patients with inflammatory bowel disease, extensive bowel resection, immune enteritis, intestinal obstruction or chronic diarrhea;
• • 19. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;
• • 20. Had a history of autologous or allogeneic stem cell transplantation;
• • 21. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;
• • 22. A history of severe neurological or psychiatric illness;
• • 23. Received other unmarketed investigational drugs or treatments within 4 weeks before randomization;
• • 24. Subjects who were scheduled to be vaccinated or received live vaccine within 28 days before study randomization;
• • 25. Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.